BOTHELL, Wash., Jan. 25 /PRNewswire-FirstCall/ -- Lumera Corp.
(Nasdaq: LMRA) announced it has acquired the exclusive rights to Helix
Biopharma's (HBP.TO) Heterodimer Protein Technology (HPT). The technology
moves Lumera closer to launching a unique product set aimed to capitalize on
the multi-billion dollar proteomic array market.
"When combined with Lumera's existing NanoCapture(TM) Array (NCA)
technology, the HPT surface chemistry allows us to bring a new level of value
to researchers and scientists concerned with protein research," said Lumera
Chief Executive Officer Tom Mino. "The acquisition of this technology
showcases Lumera's core competency of bringing important intellectual property
to the commercial marketplace, and in this instance, could revolutionize the
biochip industry by making protein arrays a reality."
The combination of the Helix HPT technology and Lumera's proprietary
nanosurface modification chemistry will, for the first time, allow researchers
to consistently take existing DNA arrays to produce protein arrays that
accurately mimic the native living cell environment of the body.
This capability could have a significant impact on the diagnostic
capabilities of researchers. By enabling researchers to evaluate, with more
clarity and accuracy, the impact of various proteins on living cells there may
be significant time and cost improvements to many important elements of
commercial research including drug screening and toxicology testing.
"We can now produce and capture proteins on a silicon chip surface while
keeping proteins fully functional," said Lumera Chief Technology Officer
Robert Petcavich. "Combining HPT selective capture chemistry with our chip
manufacturing and surface chemistries provides a biologically compatible
surface perfectly suited for printing DNA or proteins. Already, we have
produced prototype NCA's and carried out enzymatic, binding and proteomic
studies with outstanding results."
Lumera will target drug screening, toxicity, protein-protein interaction
pathways and selected diagnostic applications. Lumera plans to begin shipping
product based on the technology in 2005.
Lumera has become a nanotechnology market leader by developing proprietary
technologies and by licensing and commercializing technology products based on
exclusive intellectual property. Previously, Lumera has announced exclusive
licensing agreements with the University of Washington and Arizona
Lumera is an emerging leader in the field of nanotechnology. The company
designs proprietary molecular structures and polymer compounds for a broad
range of electro-optic, RF and specialty coating applications. The company
also has developed proprietary processes for fabricating such devices. For
more information, please visit http://www.lumera.com/.
Certain statements contained in this release are forward-looking
statements that involve a number of risks and uncertainties. Factors that
could cause actual results to differ materially from those projected in the
company's forward-looking statements include the following: market acceptance
of our technologies and products; our ability to obtain financing; our
financial and technical resources relative to those of our competitors; our
ability to keep up with rapid technological change; government regulation of
our technologies; our ability to enforce our intellectual property rights and
protect our proprietary technologies; the ability to obtain additional
contract awards and to develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products; and other risk factors identified from time to time in the
company's SEC reports, including in its Annual Report on 10-K for the year
ended December 31, 2003, and its Quarterly Reports on Form 10-Q.
SOURCE Lumera Corp.